Received Jun 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | Y018398 | OT |
no adverse event; interrupted schedule of GARDASIL-9.; This Spontaneous report was received from Other health professional and referred to a/an patient of unknown age and gender. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On an unknown date, patient started therapy with human papillomavirus 9-valent vaccine, recombinant suspension for injection (0.50 mL) (Batch/Lot Number: Y018398) (Expiration date: 04-Nov-2026) via Intramuscular (Dose Text: 0.5 mls IM once). The patient started therapy with human papillomavirus 9-valent vaccine, recombinant suspension for injection for the treatment of prophylaxis, On 05-Feb-2026, the patient experienced interrupted schedule of GARDASIL-9. (Inappropriate schedule of product administration). On an unknown date, the patient experienced no adverse event (No adverse event). The action taken with human papillomavirus 9-valent vaccine, recombinant suspension for injection regarding Inappropriate schedule of product administration was Not applicable with Not Applicable dechallenge and rechallenge results. Case Assessments: human papillomavirus 9-valent vaccine, recombinant suspension for injection regarding No adverse event with Not Applicable dechallenge and rechallenge results. The Other health professional considered the event No adverse event (,) to be not assessed to human papillomavirus 9-valent vaccine, recombinant suspension for injection and the event Inappropriate schedule of product administration (,) to be not assessed to human papillomavirus 9-valent vaccine, recombinant suspension for injection The Other health professional considered the event Inappropriate schedule of product administration to be non-serious and the event No adverse event to be non-serious